Homing Desires: Transnational Queer Migrants Negotiating Homes and Homelands

A vast literature on the home across sociology, human geography and cognate disciplines has mapped out home as a messy conceptual terrain. Critical perspectives have theorised home as simultaneously imaginative and material, and argued for the importance to pay attention to both dimensions. Following in this tradition, empirical research has explored how ‘home’ is understood, imagined and experienced in everyday life, and how imagery and experiences of home are inflected by class, race/ethnicity, migrancy, gender, sexuality, age and able-bodiness. In the literature on home, however, migrancy and sexuality are rarely brought together. This article advances existing debates on the home though an intersectional exploration of the home/migration/sexuality nexus, drawing on research with queer migrants from Central Eastern Europe (CEE) and the Former Soviet Union (FSU) living in Scotland. Methodologically, the article draws on photo diaries and photo elicitation interviews to explore queer migrants’ sense of home: an approach that allows us to untangle the spatial, material, imaginary, affective and temporal dimensions of home. Empirically, we show how both migrancy and sexuality inform our participants’ complex experiences and understandings of home. Conceptually, the article brings into conversation literatures on the migrant and the queer home, which have hitherto been largely separate, and proposes ways to advance the exploration of the home/migration/sexuality nexus

Homing desires: transnational queer migrants negotiating homes and homelands in Scotland

A vast literature on the home across sociology, human geography and cognate disciplines has mapped out home as a messy conceptual terrain. Critical perspectives have theorised home as simultaneously imaginative and material, and argued for the importance to pay attention to both dimensions. Following in this tradition, empirical research has explored how ‘home’ is understood, imagined and experienced in everyday life, and how imagery and experiences of home are inflected by class, race/ethnicity, migrancy, gender, sexuality, age and able-bodiness. In the literature on home, however, migrancy and sexuality are rarely brought together. This article advances existing debates on the home though an intersectional exploration of the home/migration/sexuality nexus, drawing on research with queer migrants from Central Eastern Europe (CEE) and the Former Soviet Union (FSU) living in Scotland. Methodologically, the article draws on photo diaries and photo elicitation interviews to explore queer migrants’ sense of home: an approach that allows us to untangle the spatial, material, imaginary, affective and temporal dimensions of home. Empirically, we show how both migrancy and sexuality inform our participants’ complex experiences and understandings of home. Conceptually, the article brings into conversation literatures on the migrant and the queer home, which have hitherto been largely separate, and proposes ways to advance the exploration of the home/migration/sexuality nexus

The politics of age and generation at the GAZE International LGBT Film Festival in Dublin

Despite their global proliferation, queer film festivals, like film festivals more broadly, are somewhat understudied within the social sciences. This is despite scholarship within film studies that argues that they are significant sites of queer collectivity and sociality. This article examines queer film festivals as sites for the production of community and queer bonds. The authors argue that questions of age, temporality and intergenerationality are central to discourses of community mobilized by festival organizers. The article draws on empirical material from a qualitative study of the GAZE International LGBT Festival in Dublin – which formed part of a larger comparative study of the cultural activist politics of queer film festivals in Europe. Ken Plummer has argued for a greater appreciation of the role of time and generation within sexuality studies. Age, temporality and intergenerationality emerged as important issues within interviews conducted with organizers and volunteers at the festival. The analysis of these issues focuses on three key themes: (1) GAZE as a site of intergenerational community; (2) GAZE as a site of remembrance; and (3) demography and the sustainability of the festival. The article argues that the festival provides a distinctive site of intergenerational queer bonds; and that despite the creation of transnational spaces and discourses, references to the nation and national identity remain central to bonding experiences at the festival

Making Different Differences: Representation and Rights in Sexuality Activism

This paper argues that current iterations of lesbian, gay, bisexual, transgender and intersex (LGBTI) rights are limited by an overreliance on particular representations of sexuality, in which homosexuality is defined negatively through a binary of homosexual/heterosexual. The limits of these representations are explored in order to unpick the possibility of engaging in a form of sexuality politics that is grounded in difference rather than in sameness or opposition. The paper seeks to respond to Braidotti’s call for an “affirmative politics” that is open to forms of creative, future-oriented action and that might serve to answer some of the more common criticisms of current LGBTI rights activism

Here Versus There: Creating British Sexual Politics Elsewhere

This reflection draws upon two recent ‘moments’ in British sexuality politics—a series of Parliamentary debates on Global LGBT rights and Brighton Pride’s campaign to ‘Highlight Global LGBT Communities’. It contrasts these two moments in order to demonstrate how, at a time when LGBT rights have ostensibly been ‘won’ in the UK, there is an increasing tendency to shift focus to the persecution of SOGI minorities elsewhere in the world. This shift in focus sets up a binary of here versus there that is politically persuasive but ultimately limited and limiting. By reflecting on the way that this growing trend of creating sexual politics elsewhere occurs in two very different locations in British politics and activism, we seek to begin a conversation about the relational affects of placing sexual politics ‘elsewhere’

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570